In 2007, Second Sight of New York, Inc., changed its name to: "Doorish Ophthalmic Technologies, Inc. "

The objective of the Company and its current management is to produce a medical device (protected by United States Patent Numbers: 5,836,996 and 5,865,839) that will function in a clinically useful manner for those persons suffering from blindness. The initial candidates for this procedure are people suffering from retinitis pigmentosa (RP) or age related macular degeneration (AMD) that have been declared totally blind. The device could also be used for patients who are not totally blind, but have lost the majority of their sight, particularly their central vision. To that end, there are two designs for the device one is a larger device, termed the Artificial epiRetinal Prosthesis (AeRP) and is more powerful while the other is a MINI AeRP which is less powerful but will be easier to implant.

Age related macular degeneration (AMD) currently affects more than 10,000,000 Americans. Approximately 700,000 additional Americans become afflicted each year. AMD is the leading cause of legal blindness in adults over the age of 55. Because the average age of the US population continues to increase and is expected to continue to increase, AMD is expected to affect more than 20 million people by the year 2025. It is also believed that a device such as the (AeRP) could help other conditions causing total blindness, including genetic conditions.

AMD and RP as well as several genetic and possibly other medical and/or physical problems such as people who have lost an eye in accident, etc.Such conditions can cause total or partial blindness. Most conditions that cause retinal blindness begin with a deterioration of the natural photoreceptor layer (PRL) in the posterior of the retina. The PRL absorbs light and initiates a photoelectrical process that sends information into the brain's visual system and results in sight. Destruction of this PRL ultimately stops the natural flow of information into the visual system. Any device seeking to restore vision must replace this function by an artificial means. Since this area of study involves several scientific disciplines, an interdisciplinary approach is necessary for solving the problem. Basic physics of Nature are involved. The AeRP is basically a small optical computer that fits into the intraocular space of the eye and mimics the natural behavior of the PRL in order to send photoelectrical information into the visual system and restore sight.

A highly skilled interdisciplinary team of scientists from DoorishTech, Inc., and Columbia University are responsible for the development of the AeRP.

The project is structured in several Phases. Phase I and Phase II are completed. They entailed the building and testing in a laboratory situation, of a set of First Generation Prototypes (FGP) as well as a study on the feasibility study of the Second Generation Prototype (SGP). Both Phases were completed successfully. The SGP is a more complex device than the FGP. It will be tested before implantation. The market for such devices is, unfortunately, large. Hopefully, this device will help the blind to regain sight in a useful manner.